Management of Renal Carcinoma During Pregnancy

Article

Laparoscopic treatment during pregnancy is becoming an option for more women.

Renal carcinoma during pregnancy is rare. Only 1 of 500 women who will need some type of non-obstetrical abdominal surgery during pregnancy, with most cases involving acute appendicitis or cholecystitis, followed by ovarian masses, symptomatic hernias, and other rare illnesses.

Authors of a recent review article published in Clinical Genitourinary Cancer focused on the laparoscopic treatment of renal cell cancer during pregnancy.

Treatment
Laparoscopic treatment during pregnancy is becoming an option for more women. 

Either radical nephrectomy or nephron-sparing surgery is necessary in patients with renal cell cancer. Even with metastatic disease, radical nephrectomy is done in advance of systemic therapy. In those with T1 stage tumors, nephron-sparing surgery is recommended.

Patients who have renal masses that cannot be treated with nephron-sparing surgery should receive laparoscopic radical nephrectomy, per the European Association of Urology. The authors pointed out that considering there have been only a small number of cases involving radical nephrectomy in pregnancy, there are even fewer cases involving nephron-sparing surgery, thus leaving little data for study.

Historically, laparoscopy during pregnancy has been considered dangerous and to be avoided at all costs due to concerns over miscarriage, teratogenesis, preterm birth, and hypercapnia. With advances in surgical instrumentation and skills, however, this notion has been dispelled. Today, laparoscopic urologic surgery is more common-even in pregnancy.

Experts recommend that for non-emergent surgical treatments during pregnancy, surgery be done during the second trimester, so to minimize risks of spontaneous abortion during the first trimester and preterm labor during the third trimester.

“This has led some authors to suggest delaying surgery until the second trimester and that the gestational age limit for successful completion of laparoscopic surgery during pregnancy should be 26 to 28 weeks,” wrote the reviewers.

Approach
Two approaches examined by the reviewers include the transperitoneal approach and the retroperitoneoscopic approach.

“The choice of the laparoscopic approach depends on the surgeon and his laparoscopic experience. Selected tumors may be approached by either route or the other, according to the surgeons’ preference, the location, and technical complexity of the renal mass,” wrote authors, led by Lucio Dell’Atti, Department of Urology, University Hospital “Ospedali Riuniti” and Polythecnic University of Marche Region, Ancona, Italy.
The transperitoneal approach has usually been employed for anterior or lateral masses. Advantages of the transperitoneal route include a larger work space resulting in wider angulation and maneuverability with instrumentation, as well as increased orientation with respect to anatomic landmarks. One disadvantage of this approach is that it necessitates bowel mobilization to uncover the kidney.

The retroperitoneoscopic approach has usually been employed with posterior, posteromedial, or posterolateral renal tumors. Advantages of this approach include the avoidance of bowel mobilization and the provision of direct access to the kidney and renal vessels. Disadvantages of this approach include a smaller retroperitoneal working space, as well as a compromised view.

Robotic-assisted laparoscopic partial nephrectomy
“There is evidence observed in the literature that shows the successful implementation of robotic-assisted laparoscopic partial nephrectomy,” wrote the authors.

Lastly, the authors cited a 2007 case that resulted in no complications as support for the safety and feasibility of laparoscopic nephroid-sparing surgery.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Related Content